Daniel Weiss is a Respiratory physician. ClinicalTrials.gov lists 12 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
111 Colchester Ave
Burlington, VT 054050001
Telephone
802-847-6177Registry record last updated 11 Sept 2025.
Clinical trials
- Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Sponsor: Schrödinger, Inc.
- DESENSITIZE-PD: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Support Dopaminergic Desensitization in PD
Sponsor: University Hospital Tuebingen
- Subthalamic Steering for Therapy Optimization in Parkinson's Disease
Sponsor: University Hospital Tuebingen
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
4 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20251 payment
- ABBVIE INC.Program year20241 payment
- United Therapeutics CorporationProgram year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
79.3%beta2-Adrenergic Agonist44.4%Albuterol Sulfate Hfa75%Ventolin Hfa25%Part D<11 patientsCorticosteroid17%Symbicort52%Arnuity Ellipta48%Part D<11 patients+ 2 more classes in this area
Metabolism & gastrointestinal
11.1%Corticosteroid11.1%Prednisone100%Part D≥12 patientsAnti-infectives
9.6%Macrolide Antimicrobial9.6%Azithromycin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
21 NIH research awards on record, funded 2001–2025 per NIH RePORTER. The latest:
- Continued Clinical Development of a Novel Pleural and Tracheal Sealant
University of Vermont & St Agric College
FY2025$367,000R33HL171782 - Extracellular Matrix Regulation of Airway Epithelial Homeostasis
University of Vermont & St Agric College
FY2025$229,200R21HL175617 - Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Lung Diseases
University of Vermont & St Agric College
FY2025$35,000R13HL182312
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Tim Driscoll
The University of Sydney
Francesco Saverio Violante
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola
Mark A. Rubin
University of Bern
Marc Humbert
Inserm
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”